373 related articles for article (PubMed ID: 24103141)
1. Safety of once-daily insulin detemir in patients with type 2 diabetes treated with oral hypoglycemic agents in routine clinical practice.
Ross S; Dzida G; Ji Q; Kaiser M; Ligthelm R; Meneghini L; Nazeri A; Orozco-Beltran D; Pan C; Svendsen AL;
J Diabetes; 2014 May; 6(3):243-50. PubMed ID: 24103141
[TBL] [Abstract][Full Text] [Related]
2. Effect of once-daily insulin detemir on oral antidiabetic drug (OAD) use in patients with type 2 diabetes.
Vora J; Caputo S; Damci T; Orozco-Beltran D; Pan C; Svendsen AL; Sølje KS; Khunti K;
J Clin Pharm Ther; 2014 Apr; 39(2):136-43. PubMed ID: 24329524
[TBL] [Abstract][Full Text] [Related]
3. [Once daily insulin detemir in patients with type 2 diabetes: results of German centers in a 6-month international observational study (SOLVE)].
Liebl A; Wilhelm B; Kaiser M
MMW Fortschr Med; 2012 Dec; 154 Suppl 4():102-9. PubMed ID: 23326928
[TBL] [Abstract][Full Text] [Related]
4. Safety and effectiveness of insulin detemir in combination with oral antidiabetic agents in an outpatient specialist setting: results of the Italian SOLVE™ observational study.
Caputo S; Maran A; Mannino D; Morano S; Lastoria G; Nicoziani P
Minerva Endocrinol; 2015 Dec; 40(4):249-58. PubMed ID: 26551483
[TBL] [Abstract][Full Text] [Related]
5. Real-world rates, predictors, and associated costs of hypoglycemia among patients with type 2 diabetes mellitus treated with insulin glargine: results of a pooled analysis of six retrospective observational studies.
Xie L; Wei W; Pan C; Baser O
J Med Econ; 2013 Sep; 16(9):1137-45. PubMed ID: 23859434
[TBL] [Abstract][Full Text] [Related]
6. Weight-neutral effect of once-daily insulin detemir in Chinese type 2 diabetes patients: subgroup analysis of the SOLVE study.
Pan C; Han P; Ji L; Ji Q; Lu J; Lin J; Liu J; Su B; Shi J; Wang P
J Diabetes; 2015 Mar; 7(2):222-30. PubMed ID: 24909984
[TBL] [Abstract][Full Text] [Related]
7. Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients: the PREDICTIVE BMI clinical trial.
Fajardo Montañana C; Hernández Herrero C; Rivas Fernández M
Diabet Med; 2008 Aug; 25(8):916-23. PubMed ID: 18959604
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of insulin detemir in clinical practice: 14-week follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVE European cohort.
Dornhorst A; Lüddeke HJ; Sreenan S; Koenen C; Hansen JB; Tsur A; Landstedt-Hallin L
Int J Clin Pract; 2007 Mar; 61(3):523-8. PubMed ID: 17313628
[TBL] [Abstract][Full Text] [Related]
9. A study comparing insulin lispro mix 25 with glargine plus lispro therapy in patients with Type 2 diabetes who have inadequate glycaemic control on oral anti-hyperglycaemic medication: results of the PARADIGM study.
Bowering K; Reed VA; Felicio JS; Landry J; Ji L; Oliveira J
Diabet Med; 2012 Sep; 29(9):e263-72. PubMed ID: 22672081
[TBL] [Abstract][Full Text] [Related]
10. [The safety and effectiveness of once daily detemir in patients with type 2 diabetes previously failing oral agents: the Chinese cohort from SOLVE(TM) observational study].
Pan CY; Ji LN; Lu JM; Yang WY; Zhou ZG; Zou DJ; Ji QH; Han P; Liu J; Li Q; Su BL; Li YB; Gao ZN; Wang PH; Yin SN; Dong YH; Yang T; Sun K; Li H; Hong X; Lin J; Shi JM; Yang XJ; Fang H; Yan XD;
Zhonghua Nei Ke Za Zhi; 2013 Jan; 52(1):11-5. PubMed ID: 23710808
[TBL] [Abstract][Full Text] [Related]
11. Hypoglycemia rates with basal insulin analogs.
Little S; Shaw J; Home P
Diabetes Technol Ther; 2011 Jun; 13 Suppl 1():S53-64. PubMed ID: 21668338
[TBL] [Abstract][Full Text] [Related]
12. Severe hypoglycemia is associated with antidiabetic oral treatment compared with insulin analogs in nursing home patients with type 2 diabetes and dementia: results from the DIMORA study.
Abbatecola AM; Bo M; Barbagallo M; Incalzi RA; Pilotto A; Bellelli G; Maggi S; Paolisso G;
J Am Med Dir Assoc; 2015 Apr; 16(4):349.e7-12. PubMed ID: 25669671
[TBL] [Abstract][Full Text] [Related]
13. Biphasic insulin aspart 30 three times daily is more effective than a twice-daily regimen, without increasing hypoglycemia, in Chinese subjects with type 2 diabetes inadequately controlled on oral antidiabetes drugs.
Yang W; Ji Q; Zhu D; Yang J; Chen L; Liu Z; Yu D; Yan L
Diabetes Care; 2008 May; 31(5):852-6. PubMed ID: 18268073
[TBL] [Abstract][Full Text] [Related]
14. The safety and efficacy of adding once-daily insulin detemir to oral hypoglycaemic agents in patients with type 2 diabetes in a clinical practice setting in 10 countries.
Khunti K; Caputo S; Damci T; Dzida GJ; Ji Q; Kaiser M; Karnieli E; Liebl A; Ligthelm RJ; Nazeri A; Orozco-Beltran D; Pan C; Ross SA; Svendsen AL; Vora J; Yale JF; Meneghini LF;
Diabetes Obes Metab; 2012 Dec; 14(12):1129-36. PubMed ID: 22830956
[TBL] [Abstract][Full Text] [Related]
15. Improved glycaemic control with no weight gain: a 26-week, open label, non-randomised, non-interventional observational study on type 2 diabetes subjects using insulin detemir.
Tripathi S; Chandalia HB; Rao PV; Badgandi M; Patni R; Subbanna PK; Shetty R; Kumar H
J Indian Med Assoc; 2011 Apr; 109(4):275-8. PubMed ID: 22187803
[TBL] [Abstract][Full Text] [Related]
16. More satisfied, but why? A pooled patient-level analysis of treatment satisfaction following the initiation of insulin glargine vs. comparators in insulin-naïve patients with type 2 diabetes mellitus.
Polonsky W; Traylor L; Wei W; Shi R; Ameer B; Vlajnic A; Nicolucci A
Diabetes Obes Metab; 2014 Mar; 16(3):255-61. PubMed ID: 24028669
[TBL] [Abstract][Full Text] [Related]
17. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain: 52-week data from the PREDICTIVE study in a cohort of French patients with type 1 or type 2 diabetes.
Marre M; Pinget M; Gin H; Thivolet C; Hanaire H; Robert JJ; Fontaine P
Diabetes Metab; 2009 Dec; 35(6):469-75. PubMed ID: 19914118
[TBL] [Abstract][Full Text] [Related]
18. Comparison of efficacy and safety of once- versus twice-daily insulin detemir added on to oral antidiabetics in insulin-naive type 2 diabetes patients: 24-week, crossover, treat to target trial in a single center.
Cander S; Dizdar OS; Oz Gul O; Guclu M; Unal OK; Tuncel E; Erturk E; Imamoglu S; Ersoy C
Prim Care Diabetes; 2014 Oct; 8(3):256-64. PubMed ID: 24522170
[TBL] [Abstract][Full Text] [Related]
19. Exenatide once weekly versus daily basal insulin as add-on treatment to metformin with or without a sulfonylurea: a retrospective pooled analysis in patients with poor glycemic control.
Grimm M; Li Y; Brunell SC; Blase E
Postgrad Med; 2013 Sep; 125(5):101-8. PubMed ID: 24113668
[TBL] [Abstract][Full Text] [Related]
20. Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: Chinese PRESENT study.
Gao Y; Guo XH; Vaz JA;
Diabetes Obes Metab; 2009 Jan; 11(1):33-40. PubMed ID: 18494806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]